Stevanato Group S.p.A. (STVN) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $16.26, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Overbought (RSI 80).
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two... Read more
Hold if already holding. Not a fresh buy at $16.26, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Overbought (RSI 80). Chart setup: Death cross but MACD improving, RSI 80. Mixed signals. Hold existing position. Score 5.9/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $16.26, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Overbought (RSI 80). Chart setup: Death cross but MACD improving, RSI 80. Mixed signals. Hold existing position. Target $21.51 (+32.3%), stop $15.12 (−7.5%), A.R:R 2.1:1. Score 5.9/10, moderate confidence.
Take-profit target: $21.51 (+32.3% upside). Target $21.51 (+32.3%), stop $15.12 (−7.5%), A.R:R 2.1:1. Stop-loss: $15.12.
Earnings in 7 days (event risk); Overbought (RSI 80); Below 200-MA, MA slope -6.4%/30d (confirmed downtrend).
Stevanato Group S.p.A. trades at a P/E of 27.1 (forward 19.0). TrendMatrix value score: 7.1/10. Verdict: Hold.
17 analysts cover STVN with a consensus score of 4.2/5. Average price target: $25.
What does Stevanato Group S.p.A. do?Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide...
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.